Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs Observation in Resected Gastric Cancer (CAPOGA)
NCT03817268Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jan 2019
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in gastric adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Disease-free survival at 5 years. Started Jan 2019; status: recruiting.
02
Drugs
capecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03817268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817268.